Department of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas.
Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Pract Radiat Oncol. 2018 May-Jun;8(3):145-152. doi: 10.1016/j.prro.2018.01.012. Epub 2018 Mar 12.
The purpose of this guideline is to offer recommendations on fractionation for whole breast irradiation (WBI) with or without a tumor bed boost and guidance on treatment planning and delivery.
The American Society for Radiation Oncology (ASTRO) convened a task force to address 5 key questions focused on dose-fractionation for WBI, indications and dose-fractionation for tumor bed boost, and treatment planning techniques for WBI and tumor bed boost. Guideline recommendations were based on a systematic literature review and created using a predefined consensus-building methodology supported by ASTRO-approved tools for grading evidence quality and recommendation strength.
For women with invasive breast cancer receiving WBI with or without inclusion of the low axilla, the preferred dose-fractionation scheme is hypofractionated WBI to a dose of 4000 cGy in 15 fractions or 4250 cGy in 16 fractions. The guideline discusses factors that might or should affect fractionation decisions. Use of boost should be based on shared decision-making that considers patient, tumor, and treatment factors, and the task force delineates specific subgroups in which it recommends or suggests use or omission of boost, along with dose recommendations. When planning, the volume of breast tissue receiving >105% of the prescription dose should be minimized and the tumor bed contoured with a goal of coverage with at least 95% of the prescription dose. Dose to the heart, contralateral breast, lung, and other normal tissues should be minimized.
WBI represents a significant portion of radiation oncology practice, and these recommendations are intended to offer the groundwork for defining evidence-based practice for this common and important modality. This guideline also seeks to promote appropriately individualized, shared decision-making regarding WBI between physicians and patients.
本指南的目的是提供关于全乳照射(WBI)伴或不伴肿瘤床加量的分割建议,并提供治疗计划和实施方面的指导。
美国放射肿瘤学会(ASTRO)召集了一个工作组,针对 5 个关键问题进行讨论,重点是 WBI 的剂量分割、肿瘤床加量的适应证和剂量分割,以及 WBI 和肿瘤床加量的治疗计划技术。指南建议基于系统的文献回顾,并使用基于 ASTRO 批准的证据质量和建议强度分级工具的预设共识制定方法制定。
对于接受 WBI 治疗的浸润性乳腺癌患者,无论是否包括腋窝下部,首选的剂量分割方案是低分割 WBI,剂量为 4000 cGy/15 次或 4250 cGy/16 次。指南讨论了可能或应该影响分割决策的因素。是否使用加量应基于考虑患者、肿瘤和治疗因素的共同决策,工作组详细说明了建议或建议使用或不使用加量的特定亚组,以及剂量建议。在计划时,应尽量减少接受处方剂量 105%以上的乳腺组织体积,并对肿瘤床进行轮廓勾画,以确保至少 95%的处方剂量覆盖肿瘤床。心脏、对侧乳房、肺和其他正常组织的剂量应尽量减少。
WBI 代表了放射肿瘤学实践的重要组成部分,这些建议旨在为这一常见且重要治疗模式的循证实践提供基础。本指南还旨在促进医生和患者之间就 WBI 进行适当个体化、共同决策。